Adult-Use
Cantourage launches in scale segment of Frankfurt Stock Exchange
The launch takes place against the backdrop of legalisation efforts in Germany.
Stephanie Price
November 14, 2022
EDITION:
- EU
- NA
The launch takes place against the backdrop of legalisation efforts in Germany.
The company has signed an agreement with GroVida licensing two of its cannabis varieties for cultivation and commercialisation in Europe
The market is expected o grow at a CAGR of 25.04 per cent.
A new study concludes that conventional pharmaceutical manufacturers may benefit from investing in cannabis markets rather than lobbying against them.
The company has stated that the transaction has the potential to drive long-term value to Aurora’s existing cannabis business.
The company has reached the settlement following the suspension of shares on the AQSE stock exchange.
A new report suggests the market will grow at a CAGR of of 15.7 per cent during the forecast period of 2022 to 2028.
The company has provided an update on its activities.
“Most countries around Europe will be following the German lead,” writes Mike Sassano, CEO of Somai Pharmaceuticals.
The appointment will be made following suspension of the company’s shares from the AQSE.
We won’t spam you
© 2023 Prohibition Holdings Ltd. All Rights Reserved.